Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications

Saeidi H 1 , Bakrin IH 2 , Raju CS 3 , Ismail P 4 , Saraf M 5 , Khairul-Asri MG 6

Affiliations 

  • 1 Department of Biomedical Science, Faculty of Medicine and Health Sciences, University of Putra Malaysia, Serdang, Malaysia. Electronic address: hamidrezasaeidi@protonmail.com
  • 2 Department of Pathology, Faculty of Medicine and Health Sciences, University of Putra Malaysia, Serdang, Malaysia
  • 3 Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 4 Department of Biomedical Science, Faculty of Medicine and Health Sciences, University of Putra Malaysia, Serdang, Malaysia
  • 5 Department of Biomedical Engineering, Faculty of Engineering, University of Isfahan, Isfahan, Iran. Electronic address: moh_sarraf@yahoo.com
  • 6 Department of Urology, Faculty of Medicine and Health Sciences, University of Putra Malaysia, Selangor, Malaysia
Adv Med Sci, 2023 Sep;68(2):359-365.
PMID: 37757663 DOI: 10.1016/j.advms.2023.09.008

Abstract

Prostate cancer (PC) is the second most common cancer in men worldwide. Homologous recombination repair (HRR) gene defects have been identified in a significant proportion of metastatic castration-resistant PC (mCRPC) and are associated with an increased risk of PC and more aggressive PC. Importantly, it has been well-documented that poly ADP-ribose polymerase (PARP) inhibition in cells with HR deficiency (HRD) can cause cell death. This has been exploited for the targeted treatment of PC patients with HRD by PARP inhibitors. Moreover, it has been shown that platinum-based chemotherapy is more effective in mCRPC patients with HRR gene alterations. This review highlights the prognosis and therapeutic implications of HRR gene alterations in PC.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications